AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28441522 — intervention group
Group type: COMPARATOR
Intervention: Orange juice
Number of subjects: 62
Study 25692656 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze dried live attenuated Oka strain Varicella Vaccine (VR 795 Oka strain)
Number of subjects: 268
Study 25692656 — intervention group
Group type: COMPARATOR
Intervention: Varilrix (Oka-RIT strain)
Number of subjects: 268
Study 25692656 — intervention group
Group type: COMPARATOR
Intervention: Freeze dried live attenuated Oka strain Varicella Vaccine (VR 795 Oka strain) and Varilrix (Oka-RIT strain)
Number of subjects: 268
Study 24245914 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic physical exercise program in a thermal pool, 3 times per week over 2 months
Number of subjects: 72
Study 24245914 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 72
Study 20334535 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR 1118 0.3%
Number of subjects: 28
Study 20334535 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR 1118 0.1%
Number of subjects: 28
Study 20334535 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR 1118 1.0%
Number of subjects: 28
Study 20334535 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR 1118 5.0%
Number of subjects: 28
Study 20334535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 18509557 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy (anterior‐posterior joint mobilization over the talus) plus standard physiotherapy programme
Number of subjects: 94
Study 18509557 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy programme only
Number of subjects: 94
Study 18509557 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy plus standard physiotherapy programme
Number of subjects: 94
Study 17138733 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 15
Study 17138733 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 15
Study 14723416 — intervention group
Group type: EXPERIMENTAL
Intervention: Australian National Death Index (NDI)
Number of subjects: 5821
Study 14723416 — intervention group
Group type: EXPERIMENTAL
Intervention: Australian National Death Index (NDI) for cardiovascular deaths
Number of subjects: 5821
Study 14723416 — intervention group
Group type: EXPERIMENTAL
Intervention: Australian National Death Index (NDI) for cancer deaths
Number of subjects: 5821
Study 9808226 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet A (10 servings of fruit and vegetables each day for 15 days)
Number of subjects: 36
Study 7751524 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 0
Study 7751524 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatment with atropine
Number of subjects: 0
Study 2717665 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 24
Study 2717665 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 24
Study 2717665 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HT agonist (fluoxetine)
Number of subjects: 24
Study 2717665 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HT antagonist (ritanserin)
Number of subjects: 24
Study 142468 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide (osmotic anti-glaucoma medication)
Number of subjects: 0
Study 142468 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what control was used)
Number of subjects: 0
Study 31915792 — intervention group
Group type: EXPERIMENTAL
Intervention: Right renal artery length
Number of subjects: 50
Study 31915792 — intervention group
Group type: EXPERIMENTAL
Intervention: Left renal artery length
Number of subjects: 50
Study 31915792 — intervention group
Group type: EXPERIMENTAL
Intervention: Diameters of left renal artery
Number of subjects: 50
Study 31915792 — intervention group
Group type: EXPERIMENTAL
Intervention: Diameters of right renal artery
Number of subjects: 50
Study 31915792 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal artery diameters
Number of subjects: 50
Study 31438412 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application for medication management
Number of subjects: 0
Study 31438412 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 28746725 — intervention group
Group type: EXPERIMENTAL
Intervention: Powdered beef liver
Number of subjects: 96
Study 28746725 — intervention group
Group type: EXPERIMENTAL
Intervention: Beef meat
Number of subjects: 96
Study 28746725 — intervention group
Group type: EXPERIMENTAL
Intervention: Beef liver + meat
Number of subjects: 96
Study 28746725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 23506189 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga
Number of subjects: 60
Study 23506189 — intervention group
Group type: COMPARATOR
Intervention: Postural orientation
Number of subjects: 60
Study 22577108 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet (30 mg daily, titrated until calcium normalization)
Number of subjects: 15
Study 22577108 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet (for 3 months)
Number of subjects: 15
Study 22577108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 19485586 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication-only condition
Number of subjects: 0
Study 19485586 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined medication plus cognitive-behavioral therapy (CBT) condition
Number of subjects: 0
Study 17543129 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized albuterol (2.5 mgr)
Number of subjects: 27
Study 17543129 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized epinephrine (1 mgr)
Number of subjects: 27
Study 17543129 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 27
Study 15502430 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation program consisting of 9 sessions focusing on self-efficacy, stress management, correction of distorted thoughts, consciousness raising, and assertiveness training.
Number of subjects: 43
Study 15502430 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 43
Study 11684535 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplementation (containing RDA or 1.5 times RDA of various vitamins and minerals)
Number of subjects: 0
Study 11684535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9821232 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 2.5‐10 mg/day
Number of subjects: 21
Study 9821232 — intervention group
Group type: COMPARATOR
Intervention: Captopril 100 mg twice a day
Number of subjects: 21
Study 9821232 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 21
Study 8121291 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepacrine hydrochloride 100 mg three times daily for 7 days
Number of subjects: 16
Study 2818418 — intervention group
Group type: EXPERIMENTAL
Intervention: skin‐resistance‐level biofeedback
Number of subjects: 30
Study 2818418 — intervention group
Group type: COMPARATOR
Intervention: false‐feedback
Number of subjects: 30
Study 2818418 — intervention group
Group type: COMPARATOR
Intervention: no‐feedback
Number of subjects: 30
Study 403562 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandamine hydrochloride
Number of subjects: 0
Study 31443732 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer mentoring intervention
Number of subjects: 0
Study 31443732 — intervention group
Group type: COMPARATOR
Intervention: Social support control
Number of subjects: 0
Study 29139337 — intervention group
Group type: EXPERIMENTAL
Intervention: Error-based learning (EBL)
Number of subjects: 54
Study 29139337 — intervention group
Group type: COMPARATOR
Intervention: Errorless learning (ELL)
Number of subjects: 54
Study 26391664 — intervention group
Group type: EXPERIMENTAL
Intervention: Diallil‐Tiosulphinate, Nucipherine and Diosgenin on alternate days
Number of subjects: 120
Study 26391664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 23383047 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/r (LPV/r)
Number of subjects: 71
Study 23383047 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz (EFV)
Number of subjects: 71
Study 23383047 — intervention group
Group type: COMPARATOR
Intervention: antibiotic use
Number of subjects: 71
Study 20574663 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron (0.25 mg intravenously) and dexamethasone (8 mg intravenously) on day 1
Number of subjects: 332
Study 20574663 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron (0.25 mg intravenously) and dexamethasone (8 mg intravenously) on day 1 followed by dexamethasone 8 mg orally on days 2 and 3
Number of subjects: 332
Study 20574663 — intervention group
Group type: COMPARATOR
Intervention: Palonosetron plus dexamethasone on day 1
Number of subjects: 332
Study 20574663 — intervention group
Group type: COMPARATOR
Intervention: Palonosetron plus dexamethasone on days 1, 2, and 3
Number of subjects: 332
Study 19522441 — intervention group
Group type: EXPERIMENTAL
Intervention: New antiepileptic drugs (AED) with accurate pathogenic targets
Number of subjects: 0
Study 19522441 — intervention group
Group type: EXPERIMENTAL
Intervention: Diets as alternatives to AED
Number of subjects: 0
Study 19522441 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0
Study 19522441 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern technologies (MRI and PET)
Number of subjects: 0
Study 19522441 — intervention group
Group type: EXPERIMENTAL
Intervention: General care improvements
Number of subjects: 0
Study 17092377 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg)
Number of subjects: 10
Study 17092377 — intervention group
Group type: COMPARATOR
Intervention: Control (no orlistat)
Number of subjects: 10
Study 17140540 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental treatment (full mouth rehabilitation under general anaesthesia)
Number of subjects: 115
Study 14675922 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact Laser Vaporization (CLV)
Number of subjects: 52
Study 14675922 — intervention group
Group type: COMPARATOR
Intervention: Transurethral Resection of the Prostate (TURP)
Number of subjects: 52
Study 10705631 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of octreotide‐acetate subcutaneously one hour prior to ERCP
Number of subjects: 209
Study 10705631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 10705631 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of octreotide‐acetate
Number of subjects: 209
Study 7560226 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic Augmentin therapy (500 mg 1 h prior to surgery, 500 mg TID for 8 days)
Number of subjects: 18
Study 7560226 — intervention group
Group type: COMPARATOR
Intervention: Control group (no systemic antimicrobial therapy)
Number of subjects: 18
Study 1697419 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (150 mg)
Number of subjects: 60
Study 1697419 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin (20 mg)
Number of subjects: 60
Study 1697419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 6986240 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 167
Study 6986240 — intervention group
Group type: COMPARATOR
Intervention: Control (aluminum hydroxide and magnesium oxide)
Number of subjects: 167
Study 30999929 — intervention group
Group type: EXPERIMENTAL
Intervention: Namilumab 150 mg
Number of subjects: 108
Study 30999929 — intervention group
Group type: EXPERIMENTAL
Intervention: Namilumab 20 mg
Number of subjects: 108
Study 30999929 — intervention group
Group type: EXPERIMENTAL
Intervention: Namilumab 80 mg
Number of subjects: 108
Study 30999929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 30999929 — intervention group
Group type: EXPERIMENTAL
Intervention: Namilumab (all doses)
Number of subjects: 108
Study 28626201 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D
Number of subjects: 717
Study 28626201 — intervention group
Group type: COMPARATOR
Intervention: CRT-P
Number of subjects: 717
Study 24794075 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PSA <1.0 ng/ml
Number of subjects: 4350
Study 24794075 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PSA 1-1.9 ng/ml
Number of subjects: 4350
Study 24794075 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PSA 2-2.9 ng/ml
Number of subjects: 4350
Study 24794075 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PSA 1-1.99 ng/ml
Number of subjects: 4350
Study 24794075 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PSA 2-2.99 ng/ml
Number of subjects: 4350
Study 22718472 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT), 10 sessions, 830 nm, output power of 50 mW, fluence of 707 J/cm² (L group, n=23)
Number of subjects: 43
Study 22718472 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (P group, n=20)
Number of subjects: 43
Study 22142317 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial-coated sutures
Number of subjects: 150
Study 22142317 — intervention group
Group type: COMPARATOR
Intervention: Conventional sutures (polyglactin and poliglecaprone)
Number of subjects: 150
Study 19261230 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (ReVia) and acamprosate (Campral)
Number of subjects: 1226
Study 17908563 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week ball exercise program
Number of subjects: 25
Study 17908563 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rehabilitation training)
Number of subjects: 25
Study 17908563 — intervention group
Group type: COMPARATOR
Intervention: Experimental group vs Control group
Number of subjects: 25
Study 15687761 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program for coping with problem situations (4 weeks, total 8 hours)
Number of subjects: 31
Study 11723983 — intervention group
Group type: EXPERIMENTAL
Intervention: BTE Primus grip attachment
Number of subjects: 26
Study 11723983 — intervention group
Group type: COMPARATOR
Intervention: Jamar dynamometer
Number of subjects: 26
Study 11723983 — intervention group
Group type: COMPARATOR
Intervention: Body position (sitting vs standing)
Number of subjects: 26
Study 8988795 — intervention group
Group type: EXPERIMENTAL
Intervention: dextroamphetamine (0.25 mg/kg p.o.) + scopolamine (0.5 mg i.v.)
Number of subjects: 17
Study 8988795 — intervention group
Group type: COMPARATOR
Intervention: placebo + scopolamine
Number of subjects: 17
Study 8480681 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (900 mg/d for 4 mo)
Number of subjects: 25
Study 3435009 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal occult blood (FOB) tests
Number of subjects: 26975
Study 3435009 — intervention group
Group type: COMPARATOR
Intervention: Control group managed by family doctors in standard manner
Number of subjects: 26975
Study 30425326 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (2 hours/week for 8 weeks)
Number of subjects: 42
Study 30425326 — intervention group
Group type: COMPARATOR
Intervention: Health education talks (control group)
Number of subjects: 42
Study 30425326 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 42
Study 27909882 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss program
Number of subjects: 409
Study 26058920 — intervention group
Group type: EXPERIMENTAL
Intervention: HPgV detection among healthy blood donors
Number of subjects: 714
Study 26058920 — intervention group
Group type: EXPERIMENTAL
Intervention: HPgV detection among HBV-infected patients
Number of subjects: 714
Study 26058920 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall HPgV infection rate in Qatar
Number of subjects: 714
Study 26058920 — intervention group
Group type: COMPARATOR
Intervention: Comparison of HPgV infection rates
Number of subjects: 714
Study 26058920 — intervention group
Group type: COMPARATOR
Intervention: Association of HPgV infection with demographic factors
Number of subjects: 714
Study 26058920 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotyping of HPgV
Number of subjects: 714
Study 23562220 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/STI/pregnancy prevention curriculum only
Number of subjects: 765
Study 23562220 — intervention group
Group type: COMPARATOR
Intervention: Service learning only
Number of subjects: 765
Study 23562220 — intervention group
Group type: COMPARATOR
Intervention: HIV/STI/pregnancy prevention curriculum plus service learning
Number of subjects: 765
Study 23562220 — intervention group
Group type: COMPARATOR
Intervention: Attention control curriculum
Number of subjects: 765
Study 21666159 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuvax at 6 months of age (2D)
Number of subjects: 110
Study 21666159 — intervention group
Group type: COMPARATOR
Intervention: MMRII at 12 months of age (1D)
Number of subjects: 110
Study 21666159 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRII at 12 months of age (2D)
Number of subjects: 110
Study 19211454 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 additional months of androgen deprivation therapy
Number of subjects: 1554
Study 19211454 — intervention group
Group type: COMPARATOR
Intervention: No additional therapy (control arm)
Number of subjects: 1554
Study 16394038 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (2.99 IU rapid intravenous infusion)
Number of subjects: 30
Study 16394038 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (maximum infusion dose 10.3 +/‐ 8.2 mU/min)
Number of subjects: 30
Study 16394038 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (additional boluses as required)
Number of subjects: 30
Study 19780299 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) chemotherapy regimens
Number of subjects: 3
Study 19780299 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy with IP cisplatin
Number of subjects: 3
Study 19780299 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin-based regimen
Number of subjects: 3
Study 19780299 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy with intravenous cisplatin plus paclitaxel
Number of subjects: 3
Study 11953732 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased sedentary behaviors
Number of subjects: 13
Study 11953732 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased sedentary behaviors
Number of subjects: 13
Study 11953732 — intervention group
Group type: COMPARATOR
Intervention: Baseline sedentary behaviors
Number of subjects: 13
Study 11475726 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzheng Baozhen Decoction (FZBZD)
Number of subjects: 117
Study 11475726 — intervention group
Group type: COMPARATOR
Intervention: Zhenqi Fuzheng Granules
Number of subjects: 117
Study 11475726 — intervention group
Group type: COMPARATOR
Intervention: Radio- and chemotherapy alone
Number of subjects: 117
Study 7866914 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 IU SMC I.M.
Number of subjects: 16
Study 7866914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2768576 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin cream
Number of subjects: 32
Study 2768576 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 32
Study 780061 — intervention group
Group type: COMPARATOR
Intervention: salbutamol 8 mg tablets (2 tablets b.d.)
Number of subjects: 18
Study 780061 — intervention group
Group type: EXPERIMENTAL
Intervention: aminophylline 225 mg tablets (1 tablet b.d. increasing to 2 tablets b.d. after 1 week)
Number of subjects: 18
Study 31919501 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic seton drainage for 1 year
Number of subjects: 44
Study 31919501 — intervention group
Group type: COMPARATOR
Intervention: Anti-TNF therapy for 1 year
Number of subjects: 44
Study 31919501 — intervention group
Group type: COMPARATOR
Intervention: Surgical closure after 2 months under a short course anti-TNF
Number of subjects: 44
Study 30944458 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib-GEMOX
Number of subjects: 94
Study 30944458 — intervention group
Group type: COMPARATOR
Intervention: sorafenib
Number of subjects: 94
Study 29381988 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 172
Study 29381988 — intervention group
Group type: COMPARATOR
Intervention: Sham-acupuncture
Number of subjects: 172
Study 26355382 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-discharge patients
Number of subjects: 178
Study 26355382 — intervention group
Group type: COMPARATOR
Intervention: Inpatient controls
Number of subjects: 178
Study 23571643 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 212
Study 23571643 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical interventions
Number of subjects: 212
Study 23571643 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight women (smokers)
Number of subjects: 212
Study 23571643 — intervention group
Group type: COMPARATOR
Intervention: Obese women
Number of subjects: 212
Study 21768582 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent format
Number of subjects: 2944
Study 21768582 — intervention group
Group type: COMPARATOR
Intervention: Natural frequency format
Number of subjects: 2944
Study 21768582 — intervention group
Group type: COMPARATOR
Intervention: Variable frequency format
Number of subjects: 2944
Study 20112492 — intervention group
Group type: EXPERIMENTAL
Intervention: Dan an tang (chronic‐cholecystitis‐relieving decoction)
Number of subjects: 160
Study 20112492 — intervention group
Group type: COMPARATOR
Intervention: Xiao yan li dan Pian (bile‐draining anti‐inflammatory tablet)
Number of subjects: 160
Study 17078734 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A - rapidity of replantation
Number of subjects: 20
Study 17078734 — intervention group
Group type: COMPARATOR
Intervention: Group B - elimination of necrotic pulp and irritating stimuli
Number of subjects: 20
Study 14723643 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional discharge model (including peer support and overlap of inpatient and community staff)
Number of subjects: 0
Study 14723643 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (control group)
Number of subjects: 0
Study 10892914 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleural tent procedure
Number of subjects: 50